{"filings":[{"id":453237,"accession_number":"0001171843-26-003455","cik":101295,"company_name":"UNITED GUARDIAN INC","ticker":"UG","form_type":"8-K","filed_at":"2026-05-15T13:00:30+00:00","items":["5.07"],"status":"ready","headline":"United-Guardian shareholders elect all 7 directors, approve say-on-pay and auditor at annual meeting","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; Arthur M. Dresner received highest votes (2,532,497 for, 61,445 against).","Say-on-pay frequency set at 'every year' with 2,576,591 votes in favor.","Non-binding advisory vote on executive compensation approved (2,562,179 for, 115,843 against).","Ratification of Grassi & Co. as independent auditor for FY 2026 approved (3,566,216 for, 45,290 against).","Broker non-votes totaled 945,034 on director election and advisory proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90576,"accession_number":"0001171843-26-003193","cik":101295,"company_name":"UNITED GUARDIAN INC","ticker":"UG","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United-Guardian Q1 sales rise 16% to $2.87M; EPS $0.18 vs $0.12 YoY","event_type":"earnings","confidence":"high","bullets":["Net income $818,902 ($0.18 per share) vs $560,895 ($0.12) in Q1 2025.","Pharmaceutical sales up 24% on Renacidin demand; cosmetic ingredient sales up 21%.","Settlement income from contract manufacturer for Renacidin shutdown in 2023 boosted results.","President sees momentum from ASI resuming regular purchases and new distribution agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2872222.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100228,"accession_number":"0001171843-26-001972","cik":101295,"company_name":"UNITED GUARDIAN INC","ticker":"UG","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United-Guardian FY2025 net sales down 13% to $10.5M; net income falls to $2.1M ($0.46/share)","event_type":"earnings","confidence":"high","bullets":["Net sales $10.5M, down 13% from $12.2M in FY2024; net income $2.1M ($0.46/share) vs $3.3M ($0.71/share) prior year.","Cosmetic ingredient sales declined due to excess inventory at distributor Ashland Specialty Ingredients and weaker China demand.","Pharmaceuticals up 15%, medical lubricants up 4% YoY; Renacidin added to two major pharmacy benefit manager formularies.","Management optimistic about new marketing agreements and distributor efforts to regain market share in coming years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100227,"accession_number":"0001171843-26-000508","cik":101295,"company_name":"UNITED GUARDIAN INC","ticker":"UG","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"United-Guardian declares $0.25/share dividend, 31st consecutive year","event_type":"dividend","confidence":"high","bullets":["Cash dividend of $0.25 per share, payable Feb 17, 2026 to holders of record Feb 9, 2026.","Dividend consistent with $0.25 paid last July; marks 31st consecutive year of dividends.","President cites new distribution agreements, new personal-care products, and Renacidin sales push.","Company expects sales and earnings to continue improving based on these initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116567,"accession_number":"0001171843-25-007076","cik":101295,"company_name":"UNITED GUARDIAN INC","ticker":"UG","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United-Guardian Q3 revenue down 26% YoY; net income falls 69% to $0.06 EPS","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $2.26M vs $3.06M in Q3 2024; net income $268K vs $865K.","Nine-month revenue $7.58M (-22%); net income $1.46M (-47%); EPS $0.32 vs $0.60.","Decline driven by reduced orders from ASI for cosmetic ingredients due to tariff/geopolitical issues.","Pharmaceutical and medical sales rose 10% and 6% respectively in first nine months.","Company advancing Renacidin formulary inclusion project to boost pharmaceutical revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":7583613.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133009,"accession_number":"0001171843-25-005206","cik":101295,"company_name":"UNITED GUARDIAN INC","ticker":"UG","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United-Guardian Q2 net sales fall 16% YoY; EPS $0.14 vs $0.21","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $2.84M, down 16% YoY from $3.39M; net income $627K ($0.14) vs $956K ($0.21).","H1 net sales $5.32M, down 20% YoY; net income $1.19M ($0.26) vs $1.88M ($0.41).","Medical lubricants +12% and pharmaceuticals +11% in H1; cosmetic sales fell due to ASI inventory overstock in Asia.","Q2 sequential improvement: sales +14% and net income +12% vs Q1 2025.","Company pursuing Renacidin formulary expansion to boost pharmaceutical sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":5319352.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133008,"accession_number":"0001171843-25-004466","cik":101295,"company_name":"UNITED GUARDIAN INC","ticker":"UG","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"United-Guardian declares $0.25/share cash dividend; plans growth initiatives for Renacidin and personal care products","event_type":"dividend","confidence":"high","bullets":["Cash dividend of $0.25 per share declared; payable August 1, 2025 to stockholders of record July 25, 2025.","This is the 30th consecutive year the company has paid a dividend.","Board retained earnings to fund new growth initiatives for personal care products and a major new project for Renacidin Irrigation Solution.","No specific financial guidance or quantitative details provided for the initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149573,"accession_number":"0001171843-25-003368","cik":101295,"company_name":"UNITED GUARDIAN INC","ticker":"UG","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.02","5.05","9.01"],"status":"ready","headline":"United-Guardian appoints President Donna Vigilante to Board of Directors","event_type":"leadership","confidence":"high","bullets":["Donna Vigilante, President and 20-year veteran, appointed to Board effective May 15, 2025.","Ms. Vigilante will serve until next Annual Meeting; no additional compensation for board role.","Board also amended Code of Ethics to clarify roles, update governance, remove duplicative language.","Amendments do not constitute a waiver; Code available on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149572,"accession_number":"0001171843-25-003275","cik":101295,"company_name":"UNITED GUARDIAN INC","ticker":"UG","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"United-Guardian stockholders elect all six director nominees and approve say-on-pay at 2025 annual meeting","event_type":"other_material","confidence":"high","bullets":["All six board nominees elected; Catherine Kolinski received highest vote count (2,624,230), Ken Globus lowest (2,307,185).","Advisory vote on executive compensation frequency: 'Every year' approved with 2,509,975 votes (86.2% of votes cast).","Say-on-pay advisory proposal approved with 2,568,277 votes for (45,457 against).","Ratification of Grassi & Co. as independent auditor for FY2025 approved with 3,792,222 votes for (96.9% of shares voted)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}